Credit: AstraZeneca. Airsupra combines albuterol, a short-acting beta2-agonist, and budesonide, an inhaled corticosteroid. Airsupra ® (albuterol/budesonide) is now available for the as-needed ...
asthma, lungs The combination therapy significantly reduced the risk of severe exacerbations and improved lung function. Topline results were announced from two phase 3 studies evaluating a fixed-dose ...
LOUISVILLE, Ky. -- An investigational fixed-dose combination of a short-acting beta 2-adrenergic agonist and an inhaled corticosteroid appeared to slow the deterioration in lung function and reduce ...
Findings from a trial comparing the real-world effectiveness of asthma inhalers could reshape how children with asthma are treated. In the first randomized controlled trial to investigate the use of a ...
Please provide your email address to receive an email when new articles are posted on . The study treatment, PT027, is a potential first-in class inhaled, fixed-dose combination rescue medication ...
The researchers evaluated budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol in preventing COPD exacerbations and pneumonia hospitalizations in real-world settings. They ...
Two drugs are better than one when it comes to stopping asthma attacks in progress, a new clinical trial has found. The study, of more than 3,100 asthma patients, found that a two-drug "rescue" ...
LONDON, April 12 (Reuters) - Treating COVID-19 patients at home with a commonly-used inhaled asthma drug called budesonide can speed up their recovery, according to UK trial results on Monday which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback